Rituximab: Perspective on single agent experience, and future directions in combination trials

Critical Reviews in Oncology/Hematology

Volumn 40, Issue 1, 2001, Pages 3-16

  McLaughlin, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B cell lymphoma; CD20; Malignant lymphoma; Monoclonal antibody therapy; Rituximab

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; CD22 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HLA DR ANTIGEN; IMMUNOGLOBULIN CLASS; IMMUNOTOXIN; INTERFERON; MITOXANTRONE; MONOCLONAL ANTIBODY LYM 1; RITUXIMAB;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DRUG APPROVAL; DRUG MECHANISM; DRUG USE; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; RADIOIMMUNOTHERAPY; RESEARCH; REVIEW; STANDARD; THROMBOCYTOPENIA; TOXICITY;

EID: 0034809276     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00130-5     Document Type: Review

References (127)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
3. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
4. Human antimouse and antiglobulin responses to monoclonal antibodies
5. Replacing the complementarity-determining regions in a human antibody with those from a mouse
6. The genetic engineering of monoclonal antibodies
7. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H
8. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
9. Enhanced effector function of dimeric forms of IDEC-C2B8 (rituximab)
10. Immunotoxins: An update
11. Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies
12. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
13. Immunotoxins: Magic bullets or misguided missiles?
14. An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use
15. A new era for radiolabeled antibodies in cancer?
16. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
17. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
18. 131I] anti-B1 (anti-CD20) antibody
19. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
20. 90Y-labeled anti-CD20 monoclonal antibody
21. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma
22. Characterization of a human B lymphocyte-specific antigen
23. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
24. CD20 workshop panel report
25. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
26. Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia
27. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia
28. Low-grade lymphomas: Expression of developmentally regulated B-cell antigens
29. The B-cell surface molecule B1 is functionally linked with B cell activation and differentiation
30. 2+ conductance found constitutively in B-lymphocytes
31. The CD20 (Bp35) antigen is involved in activation of B-cells from the G0 to the G1 phase of the cell cycle
32. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines
33. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY
34. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment
35. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
36. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines
37. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody
38. Mode of action of monoclonal antibody IDEC-C2B8 against CD20 expressing lymphoma cell lines
39. B-cell killing by monospecific and bispecific α-CD20 antibodies
40. Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the β subunit of the high-affinity IgE receptor: Evidence for a family of proteins with four membrane-spanning regions
41. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia
42. A clinical trial of anti-idiotype therapy for B cell malignancy
43. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies
44. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
45. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
46. Immunotherapy of NHL with Epratuzumab (Anti-CD22 monoclonal antibody): Excellent tolerability with objective responses
47. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10
48. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
49. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A Phase II multicenter study
50. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
51. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
52. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
53. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
54. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
55. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
56. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
57. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
58. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia /small lymphocytic lymphoma: A feasible and active regimen
59. Rituxan has significant activity in patients with CLL
60. Rituximab in indolent lymphoma: The single-agent pivotal trial
61. Clinical status and optimal use of rituximab for B-cell lymphomas
62. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
63. First report on the application of the new response criteria proposed for NHL: The rituximab pivotal trial
64. PCR analysis for the t(14;18) translocation in patients with recurrent follicular lymphoma following immunotherapy with rituximab (IDEC-C2B8)
65. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
66. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
67. Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma
68. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
69. Rituximab as first-line treatment of patients with follicular lymphoma and a low-burden tumor: Clinical and molecular evaluation
70. Phase II study of rituximab (Rituxan) in patients with previously untreated low-grade or follicular non-Hodgkin's lymphoma
71. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
72. The effect of rituximab on patients with follicular and mantle cell lymphoma
73. Rituximab in the treatment of childhood B-ALL and Burkitt's lymphoma, report on three cases
74. A pilot study of anti-CD20 MoAb rituximab in AIDS-associated non-Hodgkin's lymphoma
75. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
76. Activity of rituximab in primary central nervous system lymphoma
77. Rituximab therapy of lymphocyte predominance Hodgkin's disease
78. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy
79. Stem cell function and engraftment is not affected by 'In vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
80. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL
81. Overview of posttransplant B-cell lymphoproliferative disorders
82. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
83. A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura
84. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma
85. Pilot study of rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma
86. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
87. Laboratory changes associated with rituximab treatment: A prospective study in diffuse large B-cell lymphoma patients randomized between CHOP and CHOP plus rituximab. A GELA study
88. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
89. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
90. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
91. Levels of expression of CD19 and CD20 in chronic B cell leukaemias
92. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
93. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
94. Clinical relevance of circulating CD20 in patients with chronic lymphocytic leukemia
95. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
96. Rituximab clearance of bcl-2 from peripheral blood and bone marrow from patients with relapsed low-grade or follicular lymphoma
97. Complement activation in blood and central nervous system after rituximab treatment of B-cell lymphoma
98. Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
99. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
100. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
101. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies
102. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia resistance to rituximab therapy
103. The susceptibility of freshly isolated B-non-Hodgkin lymphoma cells to rituximab and complement is determined by CD20 levels and the CD55/CD59 inhibitors
104. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
105. Antisense therapy of hematologic malignancies
106. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
107. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
108. Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas
109. Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial
110. Combination immunotherapy of low grade or follicular non-Hodgkin's lymphoma with rituximab and alpha-interferon: Interim analysis
111. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a
112. Phase II study of rituximab after priming with IFN in patients with relapsed LG/F B-cell lymphoma
113. Upregulation of CD20 expression in chronic lymphocytic leukemia cells by in vitro exposure to cytokines
114. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma
115. Attainment of molecular remission: A worthwhile goal?
116. The clinical significance of molecular response in indolent follicular lymphomas
117. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL
118. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade non-Hodgkin's lymphoma
119. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large cell lymphoma (DLCL): Interim results of a randomized GELA trial
120. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
121. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma
122. Pilot trial of infusional cyclophosphamide, doxorubicin, & etoposide (CDE) plus rituximab in HIV-associated non-Hodgkin's lymphoma
123. Combination chemo-antibody therapy with fludarabine, cyclophosphamide and rituximab achieves a high CR rate in previously untreated chronic lymphocytic leukemia
124. Excellent tolerance of rituxan when given after mitoxantrone-cyclophosphamide: An effective and safe combination for indolent NHL
125. Efficacy of rituximab in relapsed low grade B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation